Vera Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
362
- Stock Symbol
-
VERA
- Investments
-
3
- Share Price
-
$25.45
- (As of Friday Closing)
Vera Therapeutics General Information
Description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Contact Information
Website
www.veratx.comCorporate Office
- 2000 Sierra Point Parkway
- Suite 1200
- Brisbane, CA 94005
- United States
Corporate Office
- 2000 Sierra Point Parkway
- Suite 1200
- Brisbane, CA 94005
- United States
Vera Therapeutics Timeline
Vera Therapeutics Stock Performance
As of 20-Nov-2026, Vera Therapeutics’s stock price is $25.45. Its current market cap is $1.84B with 72.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $25.45 | $26.74 | $25.08 - $56.05 | $1.84B | 72.3M | 1.94M | -$5.90 |
Vera Therapeutics Financials Summary
As of 30-Sep-2026, Vera Therapeutics has a trailing 12-month revenue of $10.3M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,904,669 | 3,174,603 | 2,379,533 | 554,488 |
| Revenue | 10,277 | 0 | 0 | 0 |
| EBITDA | (428,190) | (316,094) | (165,130) | (100,161) |
| Net Income | (415,313) | (299,615) | (152,148) | (95,990) |
| Total Assets | 465,752 | 734,733 | 655,681 | 175,546 |
| Total Debt | 76,791 | 77,306 | 54,638 | 53,708 |
Vera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vera Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Vera Therapeutics Comparisons
Industry
Financing
Details
Vera Therapeutics Competitors (60)
One of Vera Therapeutics’s 60 competitors is TG Therapeutics, a Corporation company based in Morrisville, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TG Therapeutics | Corporation | Morrisville, NC | ||||
| Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Omeros | Formerly VC-backed | Seattle, WA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Vera Therapeutics Patents
Vera Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026076069-A1 | Methods related to the treatment of kidney disease | Pending | 01-Oct-2024 | ||
| WO-2022132929-A2 | Multispecific antibody molecules and uses thereof | Inactive | 16-Dec-2020 | ||
| WO-2022132929-A3 | Multispecific antibody molecules and uses thereof | Inactive | 16-Dec-2020 | ||
| AU-2021288699-A1 | Dosing of polyomavirus neutralizing antibodies | Pending | 12-Jun-2020 | ||
| CA-3186736-A1 | Dosing of polyomavirus neutralizing antibodies | Pending | 12-Jun-2020 | C07K16/084 |
Vera Therapeutics Signals
Vera Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vera Therapeutics Investments & Acquisitions (3)
Vera Therapeutics’s most recent deal was a Corporate Asset Purchase with Stanford University (Global Rights to Novel VT-109) for . The deal was made on 13-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Stanford University (Global Rights to Novel VT-109) | 13-Jan-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) | 17-Dec-2021 | Corporate Asset Purchase | Drug Discovery | ||
| PNA Innovations | 26-Apr-2021 | Merger/Acquisition | Discovery Tools (Healthcare) |
Vera Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.59 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Vera Therapeutics FAQs
-
When was Vera Therapeutics founded?
Vera Therapeutics was founded in 2016.
-
Where is Vera Therapeutics headquartered?
Vera Therapeutics is headquartered in Brisbane, CA.
-
What is the size of Vera Therapeutics?
Vera Therapeutics has 362 total employees.
-
What industry is Vera Therapeutics in?
Vera Therapeutics’s primary industry is Biotechnology.
-
Is Vera Therapeutics a private or public company?
Vera Therapeutics is a Public company.
-
What is Vera Therapeutics’s stock symbol?
The ticker symbol for Vera Therapeutics is VERA.
-
What is the current stock price of Vera Therapeutics?
As of 20-Nov-2026 the stock price of Vera Therapeutics is $25.45.
-
What is the current market cap of Vera Therapeutics?
The current market capitalization of Vera Therapeutics is $1.84B.
-
What is Vera Therapeutics’s current revenue?
The trailing twelve month revenue for Vera Therapeutics is $10.3M.
-
Who are Vera Therapeutics’s competitors?
TG Therapeutics, Aldeyra Therapeutics, Omeros, Adaptimmune Therapeutics, and Inovio Pharmaceuticals are some of the 60 competitors of Vera Therapeutics.
-
What is Vera Therapeutics’s annual earnings per share (EPS)?
Vera Therapeutics’s EPS for 12 months was -$5.90.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process